Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction

• US 10,450,610 B2
• Filed: 06/15/2016
• Issued: 10/22/2019
• Est. Priority Date: 04/18/2008
• Status: Active Grant

• Current Assignee: University of Tennessee Research Foundation (University of Teesside)
• Original Assignee: University of Tennessee Research Foundation (University of Teesside)
• Inventors: Postlethwaite, Arnold E., Gu, Weikuan
• Primary Examiner(s): Hammell, Neil P
• Application Number:
  US15/183,764
• Publication Number:
  US 20170016068A1
• Time in Patent Office: 1,224 Days
• Field of Search: None
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.

Claims

1. A method of diagnosing impaired oral immune tolerance in a human susceptible to a disease and treating the human by inducing oral immune tolerance, the method comprising

a. obtaining a sample from the human;

b. detecting whether SEQ ID NO;

1 is present in the sample,

c. diagnosing the human as having susceptibility to oral immune tolerance induction when SEQ ID NO;

1 is absent from the sample, and

d. inducing oral immune tolerance in the human by administering an effective amount of at least one orally administered antigen to the human.

2. The method of claim 1, wherein detecting whether SEQ ID NO:

1 is present in the sample comprises using fluorescence in situ hybridization (FISH).

3. The method of claim 1, wherein said disease is selected from the group consisting of asthma, Crohn'"'"'s disease, Celiac disease, multiple sclerosis, idiopathic pulmonary fibrosis, and rheumatoid arthritis.

4. The method of claim 1, wherein said disease is a sclerotic disease.

5. The method of claim 4, wherein said sclerotic disease is systemic sclerosis.

6. The method of claim 1, wherein said sample is selected from the group consisting of:

whole blood, blood plasma, urine, tears, semen, saliva, buccal mucosa, interstitial fluid, lymph fluid, meningeal fluid, amniotic fluid glandular fluid, sputum, feces, perspiration, mucous, vaginal secretion, cerebrospinal fluid, hair, skin, fecal material, wound exudate, wound homogenate, and wound fluid.

7. The method of claim 6, wherein said at least one orally administered antigen is a collagen.

8. The method of claim 7, wherein said collagen is selected from the group types consisting of:

I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, and XXVIII.